Evidence map›Paper›PMID 39860260›Full record

ArticleMolecules (Basel, Switzerland)2025

A HER2 Specific Nanobody-Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models.

Anders H Hansen, Kasper I H Andersen, Li Xin, Oliver Krigslund, Niels Behrendt, Lars H Engelholm, Claus H Bang-Bertelsen, Sanne Schoffelen, Katrine Qvortrup

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anders H HansenDepartment of Chemistry, Technical University of Denmark, 206 Kemitorvet, 2800 Kgs Lyngby, Denmark.ORCID 0000-0002-2572-9354
Kasper I H AndersenNational Food Institute, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.
Li XinDepartment of Health Technology, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.ORCID 0000-0001-6044-6782
Oliver KrigslundFinsen Laboratory, Rigshospitalet/Biotech Research and Innovation Center (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark.ORCID 0000-0002-4032-0426
Niels BehrendtFinsen Laboratory, Rigshospitalet/Biotech Research and Innovation Center (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark.
Lars H EngelholmFinsen Laboratory, Rigshospitalet/Biotech Research and Innovation Center (BRIC), University of Copenhagen, 2200 Copenhagen, Denmark.ORCID 0000-0002-6616-1232
Claus H Bang-BertelsenNational Food Institute, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.
Sanne SchoffelenThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.
Katrine QvortrupDepartment of Chemistry, Technical University of Denmark, 206 Kemitorvet, 2800 Kgs Lyngby, Denmark.

Funding

Novo Nordisk Foundation NNF20SA0066621, NNF31534-910
6 · The paper itself

Abstract

A human epidermal growth factor receptor 2 (HER2)-specific nanobody called 2Rs15d, containing a His3LysHis6 segment at the C-terminus, was recombinantly produced. Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl auristatin E-functionalized cathepsin B-sensitive payload to provide a highly homogenous nanobody-drug conjugate (NBC), which demonstrated high potency and selectivity for HER2-positive breast cancer models.

Indexed as

Antineoplastic AgentsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesSingle-Domain AntibodiesAnimalsCathepsin BCell Line, TumorFemaleHumansOligopeptidesAntineoplastic AgentsCathepsin BERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesmonomethyl auristatin EOligopeptidesSingle-Domain Antibodiesbreast cancernanobodysite-selective conjugationtargeted treatment

Identifiers

PMID39860260
PMCPMC11768052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.